Dr. Psutka describes a study of at-home prehabilitation in MIBC
May 6th 2024"We've developed the Get Moving Trial, which is a randomized controlled phase 1/2 trial to demonstrate the safety, feasibility and efficacy of a home-based pre-op program that is personalized," says Sarah P. Psutka, MD, MSc.
Dr. Li on the design of the phase 3 MoonRISe-1 trial in NMIBC
May 6th 2024"So, in the MoonRISe-1 study, we're studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every 3 months for up to 1 year, compared to intravesical chemotherapy," says Roger Li, MD.
UGN-102 treatment leads to meaningful DFS outcomes in NMIBC, regardless of prior TURBT
May 5th 2024A post hoc analysis of the phase 3 ATLAS trial showed that UGN-102 with or without TURBT induced meaningful disease-free survival and duration of response in patients with non–muscle-invasive bladder cancer.
Dr. Meeks highlights the recent innovation in bladder cancer
May 4th 2024"BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led to a bottleneck and then an explosion in the technology and the resources and the techniques to treat patients with non–muscle-invasive bladder cancer," says Joshua J. Meeks, MD, PhD.
Enzalutamide regimens increase undetectable PSA likelihood in nonmetastatic CSPC
May 4th 2024More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs if they received leuprolide alone.
Steerable ureteroscopic renal evacuation shows promise for kidney stone removal
May 4th 2024Steerable ureteroscopic renal evacuation using the CVAC Aspiration System demonstrated noninferiority vs standard ureteroscopy for kidney stone removal, according to findings from the prospective, randomized ASPIRE trial.
TAR-200 sustains impressive clinical activity in BCG-unresponsive NMIBC
May 3rd 2024Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to the latest results from the phase 2b SUNRISE-1 trial.